Loading...
Market
What will be the primary therapeutic area for Gilead's STAT6 drug by the end of 2025?
2
Resolution / Starting Odds
Dermatology • 25%
Rheumatology • 25%
Gastroenterology • 25%
Other • 25%
Official announcements from Gilead Sciences or LEO Pharma
Story
Gilead Sciences Partners with LEO Pharma, Paying $250M for Oral Drug Targeting STAT6 in Inflammatory Diseases
Jan 11, 2025, 05:03 PM
Gilead Sciences has entered into a strategic partnership with LEO Pharma, focusing on the development of an oral drug targeting STAT6, which has potential applications in treating various inflammatory diseases. As part of the agreement, Gilead will pay LEO Pharma $250 million upfront to license the drug. This collaboration aims to accelerate the development of the STAT6 program, which is expected to address unmet medical needs in the field of inflammatory diseases.
View original story
Similar markets
Infectious diseases • 25%
Cancer • 25%
Other • 25%
Neurological disorders • 25%
None of the above • 25%
Positive Phase 1 results • 25%
FDA Fast Track designation • 25%
Phase 2 initiation • 25%
No • 50%
Yes • 50%
More than 60% • 25%
20% to 40% • 25%
Less than 20% • 25%
40% to 60% • 25%
None • 25%
China • 25%
European Union • 25%
United States • 25%
None • 25%
Drug C • 25%
Drug B • 25%
Drug A • 25%
Other • 25%
Oncology • 25%
Vaccines • 25%
Respiratory • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
BEAM-101 leads • 33%
Reni-cel leads • 33%
Casgevy leads • 33%
New molecular entities • 25%
Novel biologics • 25%
Biparatopic antibodies • 25%
Other • 25%
Other strategic move • 25%
Another acquisition in oncology • 25%
Partnership with another biotech • 25%
Focus on internal development • 25%
